Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT02369458
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT02238873
- Locations
- 🇮🇱
Rabin Medical Center, Petah Tikva, Israel
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT02181218
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Duke University
- Target Recruit Count
- 13
- Registration Number
- NCT02157116
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT02073097
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT02044276
- Locations
- 🇮🇹
Teva Investigational Site 30059, Milano, Italy
🇩🇪Teva Investigational Site 32275, Koeln, Germany
🇩🇪Teva Investigational Site 32284, Aurich, Germany
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Melissa Burgess, MD
- Target Recruit Count
- 37
- Registration Number
- NCT01879085
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 10
- Registration Number
- NCT01847001
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01827163
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan-Kettering Cancer Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT01783535
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.